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Abstract
 
The clinical picture of experimental autoimmune encephalomyelitis (EAE) is critically dependent
on the nature of the target autoantigen and the genetic background of the experimental animals.
Potentially lethal EAE is mediated by myelin basic protein (MBP)–specific T cells in Lewis rats,
whereas transfer of S100
 
 
 
- or myelin oligodendrocyte glycoprotein (MOG)–specific T cells
causes intense inflammatory response in the central nervous system (CNS) with minimal disease.
However, in Dark Agouti rats, the pathogenicity of MOG-specific T cells resembles the one of
MBP-specific T cells in the Lewis rat. Using retrovirally transduced green fluorescent T cells,
we now report that differential disease activity reflects different levels of autoreactive effector T
cell activation in their target tissue. Irrespective of their pathogenicity, the migratory activity,
gene expression patterns, and immigration of green fluorescent protein
 
 
 
 T cells into the CNS
were similar. However, exclusively highly pathogenic T cells were significantly reactivated
within the CNS. Without local effector T cell activation, production of monocyte chemoattractants
was insufficient to initiate and propagate a full inflammatory response. Low-level reactivation
of weakly pathogenic T cells was not due to anergy because these cells could be activated by
specific antigen in situ as well as after isolation ex vivo.
Key words: autoimmunity of the CNS • disease model • retroviral gene transfer • 
reactivation in the CNS • multiple sclerosis
 
Introduction
 
Autoimmune responses in the central nervous system (CNS)
are notoriously unpredictable in their course and develop-
ment of neurological deficits. In multiple sclerosis (MS), for
example, myelin-directed autoimmunity may produce a
disease that rapidly progresses to cause severe disability; in
other patients, the course is relapsing–remitting, whereas in
other cases the disease remains mild and self-contained.
A similar diversity of clinical outcomes can be observed
in variants of experimental autoimmune encephalomyelitis
(EAE) animal models, which represent inflammatory aspects
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of MS. EAE can be induced by a broad spectrum of T cells
that react against a diversity of CNS antigens. But the re-
sulting neurological disease can be radically different in
character, depending on the genetics of the experimental
animals and on the specific antigen used for induction (1).
The mechanisms determining these different disease mani-
festations are still largely unknown. They could include re-
duced capacity of encephalitogenic T cells to infiltrate into
the CNS, different migration patterns within the target or-
gan, partial tolerization events due to autoantigen expres-
sion outside of the CNS, and intrinsic properties of the T
cells themselves (e.g., different cytokine pattern).
In this paper, we made use of T cell lines (TCLs) known
to transfer either strong or mild monophasic clinical EAE.
In Lewis rats, the adoptive transfer of activated myelin basic
protein (MBP)–specific T cells (T
 
MBP
 
) triggers a severe, po-
tentially lethal neurological disease associated with the in-
vasion of the CNS by T cells and large numbers of acti-
vated macrophages (2). In this model, the neurological
deficit is mediated by soluble factors produced by activated
macrophages (3). In contrast, in the same strain of rats, T
cells specific for either myelin oligodendrocyte glycopro-
tein (MOG) (T
 
MOG
 
) or the astrocyte protein S100
 
 
 
(T
 
S100
 
 
 
) fail to induce severe clinical disease despite induc-
ing an intense inflammatory response in the CNS (4–6).
However, in the context of a different genotype, in the
Dark Agouti (DA) rat, MOG-specific T cells can induce a
severe MBP-like EAE (6). Disease activity in these EAE
models is strictly controlled by the pathogenic T cells and is
reflected by inflammation rather than demyelination, thus
representing the earliest inflammatory events in MS (4–6).
Antimyelin autoantibodies are not generated after T cell
transfer alone. Immunopathological studies revealed that
the inability of T
 
MOG
 
 and T
 
S100
 
 
 
 cells to induce disease in
Lewis rats was associated with a failure to recruit activated
macrophages into the CNS, but the molecular/cellular
mechanisms involved are unknown (4–6).
Using retrovirally engineered T cells that express the gene
of green fluorescent protein (GFP), we investigated the be-
havior of these differently pathogenic TCLs in the course of
adoptive transfer EAE (tEAE). We report that reactivation of
autoreactive T cells in the target organ crucially determines
the onset and severity of clinical autoimmune disease.
Highly pathogenic T cells are intensely reactivated after en-
try into the CNS, as demonstrated by changes in their cell
surface phenotype and up-regulation of proinflammatory
cytokines. In contrast, weakly pathogenic cells undergo only
partial activation in the target organ and fail to up-regulate
the expression of proinflammatory cytokines, although they
infiltrate the CNS at equivalent numbers.
 
Materials and Methods
 
Animals and Antigens. 
 
Lewis rats were obtained from the ani-
mal facility of the Max-Planck Institute for Biochemistry, and DA
rats were obtained from Charles River Breeding Laboratories. The
animals were kept under standardized conditions at constant tem-
perature (22
 
 
 
C), controlled lighting, and free access to food and
water. The animals were used at 6–8 wk of age. MBP was purified
from guinea pig brains as described previously (7). Bovine S100
 
 
 
protein was purchased from Sigma-Aldrich. Recombinant MOG
(amino acids 1–120) was produced as described previously (8).
Mycobacterial purified protein derivative (PPD) was purchased
from the State Serum Institute. All breeding and experiments were
performed in accordance with the guidelines of the committee on
animals of the Max-Planck Institute for Neurobiology.
 
Generation and Characterization of T Cells. 
 
Generation of
GFP-transduced T cells was performed as reported previously (9).
As retroviral vector, we used the Moloney leukemia virus deriva-
tive pLXSN (11) in which the enhanced green fluorescent pro-
tein gene cDNA (CLONTECH Laboratories, Inc.) had been
integrated (pLGFPSN). Packaging cell lines producing GFP-
carrying retrovirus were established by transferring the pLGFPSN
construct into the GP
 
 
 
E 86 cells (10). T lymphocyte blasts were
expanded in IL-2–containing growth medium after 3 d of cocul-
ture. Selection with G418 and amplification of the T cells was
performed as described previously (2, 10).
 
Induction of tEAE and Animal Preparation. 
 
Adoptive transfer
of the encephalitogenic TCLs was performed by intraperitoneal
injection. The dose of T cells injected was adjusted to 5 
 
 
 
 10
 
6
 
–
10
 
7
 
 T cell blasts/animal. Animals were monitored daily by mea-
suring weight and examining disease scores (Table I).
 
Immunohistochemistry. 
 
Tissue preparation for histology and
immunohistochemical staining using mouse monoclonal antibod-
ies directed against ED1 (Camon) and W3/13 (Becton Dickin-
son) were performed as described previously (12). For immuno-
histochemical quantification, spinal cords were analyzed 4 (MBP-,
DA-MOG-EAE) or 5 d (S100
 
 
 
-, LE-MOG-EAE) after trans-
fer. After paraformaldehyde fixation, the tissues were treated as
described previously (13). Immunostained T cells (W3/13) and
monocytes/macrophages (ED1) were quantified on three ran-
domly selected complete spinal cord cross sections from the lower
thoracic level. The section area was determined using a morpho-
metrical grid. The values represent the mean 
 
 
 
 SD of at least two
individual animals/group.
 
Cell Isolation, Cytofluorometry, and FACS
 
®
 
. 
 
Single cell sus-
pensions from organs were obtained as described previously (9,
12, 14). Cytofluorometric analysis and cell sorting were performed
as described previously using FACSort™ operated by CELL-
Quest™ software (Becton Dickinson; references 9, 12). The fol-
lowing monoclonal antibodies were used for surface membrane
analysis: W3/25 (CD4; Serotec), R73 (
 
  
 
TCR), OX-6 (rat
MHC class II), OX-40 antigen (CD134), and OX-39 (CD25,
IL-2R
 
 
 
 chain) (all obtained from Becton Dickinson).
 
ELISAs. 
 
The cytokine profile of T
 
GFP
 
 cell lines was con-
trolled by IFN
 
 
 
, IL-10, IL-2, TNF
 
 
 
 (Biosource International),
and MCP-1 (Becton Dickinson) ELISAs using the recommended
protocols. Mip-1
 
 
 
 ELISA was performed using a polyclonal rab-
bit anti–Mip-1
 
 
 
 (Biosource International) and biotin-conjugated
anti–Mip-1
 
 
 
 (Serotec) antibody combination and evaluated by
streptavidin–peroxidase conjugate and orthophenylen diamine as
substrate (Sigma-Aldrich). As standard, we used recombinant rat
Mip-1
 
 
 
 (Biosource International).
 
Intracellular Staining for IFN
 
 
 
 and IFN
 
 
 
 ELISPOT Assay.
 
In-
tracellular IFN
 
 
 
 staining was performed with anti–mouse/rat
IFN
 
 
 
 antibody (clone DB-1; Becton Dickinson). Control IgG
(mouse IgG MOPC31) was purchased from Sigma-Aldrich.
Staining was performed in 96-round-well plates. After ex vivo
isolation, the cells were incubated for 5 h with 1 
 
 
 
M monensin
in supplemented DMEM 1% rat serum (no additional growth fac-
tors). After centrifugation (300 
 
g
 
 for 10 min at 4
 
 
 
C), the cells 
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were washed with PBS and fixed with 2% paraformaldehyde for
20 min. After washing in PBS, they were permeabilized using a
commercially available permeabilization buffer (Becton Dickin-
son) and incubated with primary antibody for 30 min at 4
 
 
 
C (di-
lution, 1:100). After washing twice in permeabilization buffer,
secondary RPE-Cy5–labeled goat anti–mouse antiserum (dilu-
tion, 1:25) was added to the cells for 30 min at 4
 
 
 
C. Stimulation
of cells with PMA/ionomycin (5 
 
 
 
g/ml and 1 
 
 
 
M, respectively;
Sigma-Aldrich) was performed for 3 h in supplemented DMEM
containing 10% horse serum followed by a 3-h incubation with 1
 
 
 
M monensin (Biosource International).
ELISPOT analysis was performed according to commercially
available protocols using polyclonal goat anti–rat-IFN
 
 
 
 and bio-
tinylated goat anti–rat-IFN
 
 
 
 antiserum (R&D Systems). The
ELISPOT assays were analyzed with an automated imaging sys-
tem and appropriate computer software (KS ELISPOT auto-
mated image analysis system; Carl Zeiss MicroImaging, Inc.). The
frequency of cytokine-producing cells was expressed as the differ-
ence between the mean number of spots and the mean back-
ground for each experiment. A value equal to zero was assigned
to spot frequencies smaller than the mean background of the indi-
vidual assay plus a standard deviation of two. All standard devia-
tions were 
 
 
 
20% of the mean.
 
Quantitative PCR.
 
Ex vivo–isolated T
 
MBP-GFP
 
 and T
 
S100
 
 
 
-GFP
 
cells were centrifuged (300 
 
g
 
 for 10 min at 4
 
 
 
C) and immediately
shock frozen. Spinal cord homogenates were frozen 4 and 8 h
after intrathecal S100
 
 
 
/MOG injections in TRI reagent (Sigma-
Aldrich). mRNA extraction and cDNA preparation was per-
formed using standard protocols (Sigma-Aldrich). Taqman analy-
sis was performed as reported using sequence detector “Taqman”
(ABI Prim 7700; Applied Biosystems; reference 12). For quantifi-
cation of cytokine mRNAs, the expression of a housekeeping
gene (
 
 
 
-actin) was set in relation to the cytokine mRNA. The
analyzed mRNA was extracted from 
 
 
 
0.5 
 
 
 
 10
 
6
 
 ex vivo–sorted
T
 
MBP-GFP
 
 or T
 
S100
 
 
 
-GFP
 
 cells that had been isolated and pooled
from organs of three animals. Representative data of at least two
independent experiments are shown. All PCR data were obtained
by two independent measurements. The cycle threshold value of
the measurements did not differ 
 
 
 
0.5 amplification cycles.
 
Restimulation of Ex Vivo–isolated T
 
GFP
 
 Cells. 
 
T
 
GFP
 
 cells sorted
from spleens 4 d after transfer. (5 
 
 
 
 10
 
4
 
 cells/well) were cultured
without growth factors (DMEM 1% rat serum) in 96-well plates
together with irradiated thymocytes (5,000 rad, 10
 
6 
 
cells/well) in
the presence of no antigen, 2.5 
 
 
 
g/ml Con A, 10 
 
 
 
g/ml of spe-
cific antigen (MBP, S100
 
 
 
, and MOG), or 10 
 
 
 
g/ml of irrele-
vant antigen PPD, respectively. At the same time, parallel held
T
 
GFP
 
 cell cultures were restimulated using identical conditions.
Proliferation was evaluated measuring [
 
3
 
H]dT (2 Ci/mmol; Am-
ersham Biosciences) incorporation (9).
 
Intrathecal Soluble Antigen Injection. 
 
Intrathecal injection was
performed 4 (S100
 
 
 
 EAE) or 5 d (LE-MOG EAE) after T cell
transfer. Under narcosis using 300 mg/kg chloralhydrate (Merck),
the antigens (20 
 
 
 
g S100
 
 
 
, MOG, or OVA, respectively) were
stereotactically injected into the cisterna magna. Spinal cords and
spleens were harvested 4 h after intrathecal injection, and T
 
GFP
 
cells were analyzed cytofluorometrically for the expression of acti-
vation markers as aforementioned. For histology, spinal cords
were prepared 24 h after injection. Subsequent tissue preparation
and antibody staining was performed as aforementioned.
 
RT/PCR Dot-blot Hydridization Analysis of Chemokine mRNA
Expression in CNS Tissues. 
 
RT-PCR dot-blot hydridization
(15–17) was performed to quantitate MCP-1 and MIP-1
 
 
 
Table I.
 
Characterization of Antigen-specific T
 
GFP
 
 Cell Lines
 
T
 
MBP-GFP
 
 cells T
 
S100
 
 
 
-GFP
 
 cells T
 
DA-MOG-GFP
 
 cells T
 
LE-MOG-GFP
 
 cells
Phenotype CD4
 
  
 
(
 
 
 
95%) CD4
 
  
 
(
 
 
 
95%) CD4
 
  
 
(
 
 
 
95%) CD4
 
  
 
(
 
 
 
95%)
Cytokine releasea
IFN  (ng/ml) 63 97 228 74
TNF  (ng/ml) 20 8 23 14
IL-4 (ng/ml) 0 0 0 0
IL-10 (ng/ml) 21 14 18 14
MCP-1 (ng/ml) 6 6 5 8
MIP-1  (ng/ml) 0.9 0.8 1.7 1.6
IFN -ELISPOTb
Blast T cells (SD) 282 (52) 1,767 (83) n.d. n.d.
Resting T cells (SD) 1.75 (1.5) 5 (2.5) n.d. n.d.
Specificityc
Specific Ag: cpm (SD) 2,223 (229) 8,942 (393) 12,529 (234) 10,852 (465)
Control Ag: cpm (SD) 112 (51) 53 (75) 636 (120) 339 (54)
TGFP cell lines were CD4+, Th-1–type cells, highly specific for their respective antigen. 
aCytokine release was measured in 24-h supernatant of T cell blasts. Cell concentration: 1   106 cells/ml; the SD of the duplicate measurements
never exceeded 20%. 
bSpecific dots per 100,000 cells are shown. 
cCpm incorporated with specific antigen versus cpm incorporated with control antigen (PPD) are shown. n.d., not done.Reactivation of Autoreactive T Cells in the Target Organ 188
mRNA levels before and at the beginning of clinical EAE in-
duced by TS100  and TMBP cells. The assays were performed as re-
ported previously (18). The results of initial experiments were
confirmed by analysis of a second set of samples obtained from
rats that received T cell transfers on a separate occasion. Data
shown were derived from the initial experiment.
Online Supplemental Material.  Fig. S1 shows the “migratory
phenotype” of the used GFP  TCLs, which is characterized by
down-regulation of activation markers IL-2R and OX-40 anti-
gen and up-regulation of MHC class II. Intrathecal injection of
soluble antigen locally induced mRNA of proinflammatory cyto-
kines (IFN  and IL-2) and monocyte chemoattractants (MCP-1
and Mip-1 ; Fig. S2 A), followed by increased recruitment of
monocytes/macrophages into the CNS (Fig. S2 B). Online sup-
plemental material is available at http://www.jem.org/cgi/content/
full/jem.20031064/DC1.
Results
Retroviral Transduction with GFP Does Not Modify the
Functional Phenotype of Neuroantigen-specific TCLs. MBP-,
S100 -, and MOG-specific T cells from Lewis rats (TMBP-GFP,
TS100 -GFP, and TLE-MOG-GFP cells) and MOG-specific T cells
from DA rats (TDA-MOG-GFP cells) were retrovirally engineered
to express GFP as genetic marker (9). After one to two rounds
of restimulation in vitro and expansion in the presence of
G418, these GFP-expressing TCLs were exclusively specific
for their selecting antigen and were defined as members of the
CD4  Th-1 T cell subset by their cell surface phenotype and
cytokine profile (Table I). Like their nonmanipulated counter-
parts, TMBP-GFP cells and TDA-MOG-GFP cells transferred severe
EAE to syngeneic naive recipients, whereas TS100 -GFP cells
and TLE-MOG-GFP cells were only weakly pathogenic (Table II).
Neuroantigen-specific T Cells Accumulate in the CNS Irre-
spective of Their Ability to Induce Clinical Disease. TMBP-GFP
cells acquire a migratory phenotype in the periphery before
invading the CNS of Lewis rats (12). This phenotypic
Table II. TGFP Cell–induced EAE
TMBP-GFP
cells
TS100 -GFP
cells
TDA-MOG–GFP
cells
TLE-MOG-GFP
cells
Injected T cells 5   106 107 5   106 107
Disease course
Onset (d) 3 3 3 4
Maximum (d) 6 6 5 6
Duration (d) 8 8 8 6
Disease severity
Maximal score (SD) 2.7 (0.6) 0.6 (0.5) 3.7 (0.5) 0.3 (0.5)
% Weight loss (SD) 16 (3) 8 (4) 19 (3) 9 (4)
Incidence of clinical disease 52/52 21/45 32/32 6/41
Histological analysis
W3/13  cells (SD) 427 (271) 147 (57) 250 (134) 664 (439)
ED1  cells (SD) 275 (137) 19 (26) 285 (91) 83 (50)
ED1/W3/13 ratio 1/1.6 1/7.9 1/0.9 1/8
Disease score: 0, no disease; 1, flaccid tail; 2, gait disturbance; 3, complete hind limb paralysis; 4, tetraparesis; and 5, death. (Disease course) Time
period of weight loss and/or clinical paresis. (Disease severity, Maximal score) A representative EAE experiment involving at least five animals/group
is indicated. (Weight loss) In percent of the body weight before tEAE induction. (Incidence of clinical disease) Animals with pareses/animals with
pure weight loss. (Histological analysis) Numbers of W3/13+, and ED1+ cells in spinal cord lesions (perivascular and parenchymal) per 1 mm2. 
Figure 1. Relative numbers of TGFP cells infiltrating the CNS in the
course of tEAE. The number of CNS-infiltrating GFP-positive T cells in
the CD4  cell population was analyzed 4 d after transfer. TMBP-GFP (A),
TDA-MOG-GFP (B), TS100 -GFP (C), and TLE-MOG-GFP (D) cells are shown. The
majority of CD4  T cells were GFP positive in all cell lines tested. Repre-
sentative data of at least three independent experiments/TCLs are shown.Kawakami et al. 189
change is characterized by the down-regulation of the acti-
vation markers CD25 and OX-40, and the passive adsorp-
tion of MHC class II protein (12). This phenotypic change
was seen in all neuroantigen-specific T cells transferred, ir-
respective of their antigen-specificity and pathogenic po-
tential. TMBP-GFP, TS100 -GFP, TLE-GFP, and TDA-MOG-GFP cells
showed similar patterns of CD25, OX-40, and MHC class
II expression after a sojourn of 84 h in the spleens of synge-
neic recipients (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20031064/DC1) (12).
FACS® analysis further revealed that large numbers of
these GFP-labeled T cells invaded the CNS irrespective of
their autoantigen specificity (Fig. 1). 4 d after the transfer
of TMBP-GFP, TS100 -GFP, TLE-MOG-GFP, or TDA-MOG-GFP effec-
tor T cells, the majority (75–94%) of CD4  T cells infiltrat-
ing the CNS expressed GFP (Fig. 1). In all cases, this very
Figure 2. Infiltration of W3/
13  and ED1  cells in the course
of tEAE induced by TMBP-GFP,
TS100 -GFP, TDA-MOG-GFP, and
TLE-MOG-GFP cells. Lesions in the
lumbosacral spinal cord 4 d after
transfer of TMBP-GFP (A and E),
TS100 -GFP (B and F), TDA-MOG-GFP
(C and G), and TLE-MOG-GFP (D
and H) cells mediated by tEAE
are shown. TGFP cells (green),
immunohistochemical staining
with T cell marker W3/13 (A–D,
red), and monocyte/macro-
phage marker ED1 (E–H, red).
(Arrowheads) Location of TGFP
cells (A–D) and monocytes/
macrophages (E–H). Magnifica-
tion bars, 10  m. TGFP cells of all
specificities infiltrate the CNS in
high numbers at the onset of
clinical symptoms. They can be found as well in the meningeal and perivascular areas as deep as the CNS parenchyma (A–H). ED-1–positive macro-
phages in TMBP-GFP and TDA-MOG-GFP cell–tEAE enter the CNS in high numbers where they are distributed throughout the tissue (E and G). In contrast,
TS100 -GFP and TLE-MOG-GFP cells recruit less ED1  monocytes/macrophages, which are mainly restricted to the meningeal and perivascular areas (F and
H). Representative histological sections of lumbo-sacral spinal cords of at least two independent experiments/TCLs are shown.
Figure 3. Weakly pathogenic TGFP cells show
minimal reactivation after infiltrating the target
organ. 84 h after transfer of TMBP-GFP, TDA-MOG-GFP,
TS100 -GFP, and TLE-MOG-GFP cells, the spinal cords
and spleens of recipient rats were prepared. TGFP
cells were analyzed cytofluorometrically for the
expression of the surface membrane molecules
OX-40 antigen (OX-40), IL-2R, and CD4. (IgG)
Isotype control. Shaded histograms represent
spleen-derived TGFP cells, and unshaded overlay
histograms show TGFP cells isolated simultaneously
from the CNS. Spinal cord–derived TMBP-GFP cells
(blue histograms) and TDA-MOG-GFP cells (black his-
tograms), but not TS100 -GFP cells (red histograms)
and TLE-MOG-GFP cells (yellow histograms), up-regulate
OX-40 antigen and IL-2R. Representative data of
at least four independent experiments/TCLs are
shown.Reactivation of Autoreactive T Cells in the Target Organ 190
high proportion of GFP-expressing effector T cells initially
present in the infiltrates decreased to  10% within the fol-
lowing 72 h (unpublished data).
Invasion of GFP-expressing effector T cells into the
CNS was verified by confocal immunofluorescence mi-
croscopy. Beyond confirming the FACS® data, morphol-
ogy showed similar migration patterns for all types of neu-
roantigen-specific GFP  cells. The majority of cells did not
remain in the perivascular space, but penetrated deeply into
the parenchyma (Fig. 2 and Table II). Therefore, the in-
ability of TS100 -GFP and TMOG-GFP cells to induce a signifi-
cant neurological deficit in the Lewis rat cannot be attrib-
uted to a failure to cross the blood brain barrier (BBB) and
infiltrate into the target tissue.
Activation and Proinflammatory Cytokine Expression by Ef-
fector T Cells Is a Prerequisite for Disease Induction. Upon in-
vasion of the CNS, encephalitogenic Lewis TMBP-GFP
effector cells underwent reactivation as indicated by in-
creased levels of OX-40 antigen and IL-2R (Fig. 3) and
partial down-modulation of the CD3–TCR complex on
their surface (not depicted; reference 12). Similar changes
were also seen in highly pathogenic TDA-MOG-GFP cells
when analyzed isolated from the CNS shortly after onset
of EAE 4 d after transfer (Fig. 3). In striking contrast, the
weakly pathogenic TS100 -GFP and TLE-MOG-GFP cells that in-
filtrated the CNS in equally high numbers (Figs. 1 and 2)
did not show significant up-regulation of IL-2R and OX-
40 antigen (Fig. 3), down-modulation of the CD3–TCR
complex (not depicted), nor did they induce clinical dis-
ease (Table II).
The activation status of TMBP-GFP and TS100 -GFP cells re-
covered from the CNS was investigated further by real-
time RT-PCR. Activation of rat CD4  Th-1 TCLs in
vitro leads to the rapid up-regulation of cytokines (IL-2,
IFN , and IL-10) and membrane proteins (OX-40 antigen
and IL-2R). We compared the mRNA transcription of IL-2,
IFN , IL-10, and IL-2R between TMBP-GFP and TS100 -GFP
cells cytofluorometrically sorted from either spleen or CNS
4 d after transfer, and the same TCLs maintained in parallel
in IL-2–containing cultures (Fig. 4).
Upon entry into the CNS, the pathogenic TMBP-GFP cells
markedly increased IL-2, IL-2R, IFN , and IL-10 mRNA
transcription relative to TMBP-GFP cells isolated from the pe-
riphery. In contrast, in nonpathogenic TS100 -GFP effector T
cells isolated from CNS infiltrates, we detected a significant
increase in the expression of mRNA transcripts only in the
case of IL-2, but not IFN , IL-10, or IL-2R (Fig. 4).
We compared the expression of IFN  protein in TMBP-GFP
and TS100 -GFP cells on a single cell level. FACS® anal-
ysis of TMBP-GFP cells recovered from the CNS revealed
that 15% of the cells stained positive for intracellular
IFN . In contrast, brain-infiltrating TS100 -GFP effector T
cells did not express IFN  in measurable amounts, al-
though they clearly did so after stimulation with PMA/
ionomycin (Fig. 5). ELISPOT analysis of TMBP-GFP and
TS100 -GFP cells during the 24-h period directly after isola-
tion from spleen and CNS confirmed the distinct ex-
pression patterns of IFN  by TMBP-GFP cells on protein
secretion levels, and again showed that brain-infiltrating
TS100 -GFP effector T cells failed to release IFN  in mea-
surable amounts (Fig. 5 I).
Neuroantigen-specific T Cells Are Not Anergized. The
failure of the CNS to activate infiltrating S100  and
MOG-specific T cells in the Lewis rat could be explained
if T cells with these specificities were rendered function-
ally unresponsive. Therefore, we isolated TS100  GFP,
TMBP-GFP, TLE-MOG-GFP, and TDA-MOG-GFP cells from the
spleen 4 d after transfer and immediately confronted them
with their cognate antigen in vitro (Table III). Irrespective
of their antigen specificity or ability to induce clinical
EAE, all four TCLs retained their ability to proliferate in
response to their cognate antigen in vitro (Table III).
Figure 4. IFN , IL-10, and
IL-2R mRNA of TGFP cells
within the CNS. mRNAs of
TMBP-GFP and TS100 -GFP cells from
spleens (SPL) and spinal cords
(CNS) 84 h after transfer and
from parallel cultures (CUL) were
quantitatively analyzed for the ex-
pression of IL-2, IFN , IL-10,
and IL-2R. TMBP-GFP cells (blue
columns), but not TS100 -GFP cells
(orange columns), up-regulated
the expression of IFN , IL-10,
and IL-2R upon infiltration into
the spinal cord. Specific copies of
mRNA in relation to the house-
keeping   -actin mRNA are
shown. Ex vivo TGFP cells were
obtained from three animals and
measured in two independent
quantitative PCR reactions.Kawakami et al. 191
Furthermore, intracellular IFN  staining revealed that
TS100  GFP and TLE-MOG-GFP cells isolated from spleen and
CNS can be induced to express IFN  after stimulation
with PMA/ionomycin in vitro (Fig. 5, G and H, and Fig.
6 D). Therefore, the inability of certain T cell specificities
to induce clinical EAE in the Lewis rat cannot be attrib-
uted to anergy.
Activation of CNS-infiltrated TGFP Cells by Intrathecal Anti-
gen Injection Aggravates EAE. To test whether enhanced
activation of weakly pathogenic TS100 -GFP or TLE-MOG-GFP
cells within the CNS increases their pathogenicity, we in-
jected soluble S100  or MOG antigen, respectively. In-
trathecal injection of 20  g of specific antigen, but not of
control antigen ovalbumin, clearly exacerbated clinical dis-
ease; S100  animals showed a marked increase in weight
loss (Fig. 6 A) and LE-MOG animals additionally devel-
oped pareses (Fig. 6 B). A significant number of TS100 -GFP
and TLE-MOG-GFP cells isolated from spinal cords 4 h after
S100 /MOG injection up-regulated OX-40 antigen, IL-
2R (Fig. 6 C), and produced IFN  (Fig. 6 D). These acti-
vation-related changes were restricted to TGFP cells within
the CNS (Fig. 6 D). Quantitative mRNA analyses from
spinal cords treated with specific antigen confirmed a
strong up-regulation of IFN  and IL-2R within 4 h after
intrathecal antigen injections (Fig. S2 A, available http://
www.jem.org/cgi/content/full/jem.20031064/DC1).
Partial T Cell Activation Is Insufficient to Induce the Expres-
sion of MCP-1 and MIP-1  and Fails to Recruit Macrophages
into the CNS. The neurological deficits in EAE seem to
be caused by activated macrophages recruited to the CNS
(19, 20). Indeed, CNS infiltrates induced by highly en-
cephalitogenic TMBP-GFP and TDA-MOG-GFP cells contained
Figure 5. IFN  production of TGFP cells within the CNS. Intracellular staining for IFN  of
(A) TMBP-GFP cells isolated from spleens (blue shaded histogram) and spinal cords (unshaded red
overlaid histogram) and (E) TS100 -GFP cells isolated from spleens (orange shaded histogram) and
spinal cords (unshaded blue overlaid histogram) 4 d after transfer. For control, resting (shaded
histograms) and blast T cells (unshaded overlaid histograms, 24 h after restimulation with spe-
cific antigen) of (B) TMBP-GFP cells and (F) TS100 -GFP cells were stained. Both TMBP-GFP cells
(42%) and TS100 -GFP cells (54%) up-regulated IFN  expression in vitro upon stimulation with
specific antigen (B and F). However, exclusively TMBP-GFP cells produced IFN  upon infiltra-
tion into the spinal cord (A, 15%). (C, D, G, and H) TMBP-GFP and TS100 -GFP cells isolated from
spleens (C, TMBP-GFP cells, 53%; G, TS100 -GFP cells, 72%) and spinal cords (D, TMBP-GFP cells,
43%; H, TS100 -GFP cells, 63%) could be stimulated to produce IFN  in the presence of PMA/
ionomycin. (Shaded histograms) Nonstimulated ex vivo TGFP cells. (Overlaid open histograms)
PMA/ionomycin-stimulated ex vivo TGFP cells. (I) (IFN –ELISPOT) Spontaneous IFN 
release of TMBP-GFP cells (MBP) and TS100 -GFP cells (S100 ) isolated from spleens (blue bars)
and spinal cords (pink bars) was determined after 24 h of culture. The values represent means of
quadruplicate measurements involving four (MBP-tEAE) and nine (S100 -tEAE) animals,
respectively. IFN -positive dots per 100,000 sorted cells were determined. Both TMBP-GFP cells
and TS100 -GFP cells isolated from spleens and spinal cords could be stimulated to produce IFN 
in the presence of PMA/ionomycin (not depicted).
Table III. Ex Vivo–isolated TGFP Cells Are Not Anergic
Proliferation TMBP-GFP cells TS100 -GFP cells TDA-MOG-GFP cells TLE-MOG-GFP cells
Specific Ag: cpm (SD) 628 (43) 8,358 (320) 11,574 (672) 9,166 (465)
Control Ag: cpm (SD) 26 (8) 10 (7) 181 (238) 10 (2)
Proliferation occurred when TGFP cells were isolated from spleens (n   3) 4 d after transfer and exposed to specific/control antigen (PPD) in the
presence of irradiated thymic APCs. [3H]thymidine incorporation was determined 72 h after culturing began. Triplicate values   SD are shown.Reactivation of Autoreactive T Cells in the Target Organ 192
large numbers of activated ED1  macrophages, whereas
these cells were rare in the CNS infiltrates induced by
weakly pathogenic TS100 -GFP and TLE-MOG-GFP cells (Fig. 2
and Table II). Therefore, we compared the levels of mac-
rophage-attracting CC chemokines MCP-1 and MIP-1 
(21, 22) with both types of lesion. Quantification of MCP-1
and MIP-1  mRNA transcripts by RT-PCR in Lewis
rats injected with either TMBP or TS100  cells revealed that,
in animals injected with TMBP cells, MCP-1 and MIP-1 
transcripts increased dramatically by day 4 coincident with
the onset of clinical EAE (Fig. 7). In contrast, in rats in-
jected with S100 -specific T cells, there was no corre-
sponding increase in the signals for MCP-1 and MIP-1 ,
which remained  10-fold lower than in animals with
MBP-induced EAE (Fig. 7). Therefore, partial activation of
T cells within the CNS can trigger the sustained recruit-
ment of T cells into the lesions, but it is insufficient to acti-
vate MCP-1 and MIP-1  expression, which mediate the
recruitment of macrophages into the CNS. Intrathecal in-
jection of specific antigen induced a strong increase of
MCP-1 and MIP-1  mRNA within the CNS (Fig. S2 A)
followed by concomitant recruitment of ED1  mono-
cytes/macrophages into the CNS (Fig. S2 B) and aggrava-
tion of clinical disease (Fig. 6, A and B).
Discussion
We recently used retrovirally engineered encephalitoge-
nic T cells to trace the fate of autoimmune effector T cells
before, during, and beyond clinical EAE (9, 12). These
Figure 6. Intrathecal injection
of antigen activates weakly
pathogenic TGFP cells and aggra-
vates clinical disease. Intrathecal
injection of 20  g of specific
antigen (A, S100 ; B, MOG,
closed squares and black bars) or
20  g of control antigen (OVA,
open triangles) was performed at
day 4 (A, S100 -EAE) or day 5
(B, LE-MOG-EAE) after T cell
transfer. Control animals, which
did not receive intrathecal injec-
tion, are shown (black circles).
Weight loss was monitored daily,
at day 4 (A) or 5 (B) in closer
time intervals (4/5a: 1 h before;
4/5b: 4 h after; and 4/5c: 8 h
after intrathecal S100 /MOG
injection). Animals that had re-
ceived 20  g of specific antigen
intrathecally showed enhanced
weight loss starting 8 h after
antigen  injection. Animals of
TLE-MOG-GFP cell–induced EAE
developed  clinical symptoms
reaching maximal scores of three
(B, black bars). Mean value and
standard  deviation of five in-
dependent experiments (S100 )
and three independent experi-
ments (MOG) are shown, includ-
ing eight animals/treatment group.
(C) TS100 -GFP (orange histograms)
or TLE-MOG-GFP cells (yellow histo-
grams) were isolated from spinal
cords of control antigen (shaded
histograms, 20  g OVA) or spe-
cific antigen (overlay histograms,
20  g S100  or MOG, respec-
tively)–treated animals 4 h after
intrathecal injection, and were
analyzed cytofluorometrically for the expression of IL-2R and OX-40 antigen (OX-40). TGFP cells from specific antigen-treated but not OVA-treated
animals up-regulated OX-40 antigen and IL-2R. (D) Intracellular IFN  staining of TS100 -GFP (orange histograms) or TLE-MOG-GFP cells (yellow histo-
grams) after intrathecal treatment with control antigen (shaded histograms, 20  g OVA) or specific antigen (overlay histograms, 20  g S100  or MOG,
respectively). 4 h after intrathecal antigen injection TGFP cells in the CNS (top left histogram, TS100 -GFP cells, 24% of cells were IFN  ; middle left
histogram, TLE-MOG-GFP cells, 10% of cells were IFN  ) but not in the spleen (top right histogram, TS100 -GFP cells, 2% of cells were IFN  ; middle right
histogram, TLE-MOG-GFP cells, 1% of cells were IFN  ) up-regulated IFN  production. Upon stimulation with PMA/ionomycin (unshaded over-
lay histograms), a high percentage of TLE-MOG-GFP cells isolated from CNS (bottom left histogram), and spleen (bottom right histogram) produced IFN .
Representative results of two independent sets of experiments/antigen are shown.Kawakami et al. 193
studies were performed in the classical Lewis rat EAE model
of adoptively transferred MBP-specific T cells, which pro-
duce an acute, potentially lethal clinical course. Here, we
used the same methodological approach to learn why CD4 
T cells specific for alternative brain autoantigens, or from
different rat strains, cause autoimmune responses of strik-
ingly different character. T cells specific for the astrocyte-
derived S100  antigen, for example, transfer mild clinical
EAE, yet they produce massive inflammatory infiltrates in
the recipient CNS (22). A similar pattern is seen with
MOG-specific T cells in the Lewis rat (5), whereas, in con-
trast, in DA rats, MOG-specific T cell–mediated EAE is as
violent as MBP-induced EAE in the Lewis strain (23).
We compared the behavior of both groups of encephali-
togenic T cells on several levels. We analyzed their in vitro
responsiveness, their migratory behavior, and functional
state upon transfer in vivo; we also measured their capacity
to infiltrate the target CNS tissues and, finally, local reacti-
vation within the CNS. The TCLs were all members of the
same subset of CD4 , CD8 ,  / TCR Th-1 T cells. Irre-
spective of their neuroantigen specificity, all four TCLs pro-
duced similar profiles and quantities of Th-1–associated cy-
tokines in response to antigen presented by professional
APCs in vitro. Differences in antigen specificity neither in-
fluenced phenotypic T cell maturation in vivo nor the ki-
netics of antigen-specific effector T cell recruitment into the
CNS. All the GFP-expressing T cells assumed the same mi-
gratory phenotype in vivo, in particular down-regulation of
activation markers and proinflammatory mediators (12).
The undistinguishable behavior of highly versus weakly
autoaggressive T cells before migration into the CNS may
not be unexpected because a similar behavior has been ob-
served also in T cells specific for a foreign antigen, such as
ovalbumin (12). In fact, it appears that the prodromal phase
likely excludes contacts with the specific target autoanti-
gen. It was more surprising that each type of brain-specific
T cells invaded the brain with a very similar time course
and intensity. In all models, invasion of the CNS by migra-
tory autoimmune T cells always started abruptly ( 3–4 d
p.i.), and also in all models, during the initial phases of in-
vasion, brain-specific T cells formed the majority of all
CD4 -infiltrating T cells, though with rapid decrease of
this high proportion. In contrast, migratory T cells specific
for a foreign antigen (e.g., ovalbumin) failed to accumulate
in the CNS (12). Irrespective of their pathogenic potential,
the majority of neuroantigen-specific TGFP cells migrated
deeply into the CNS parenchyma (Table II). These data are
in contrast with earlier studies of a chronic relapsing mouse
model, which located brain-specific T cells in the perivas-
cular area (24).
Migratory encephalitogenic T cells readily crossed the
BBB, provided it had been activated during the three to
four prodromal days preceding EAE, but they are excluded
by a resting BBB (12). The processes involved in BBB acti-
vation are still unknown. It has been speculated (25, 26)
that a few highly activated T cells, which enter the CNS
within the first few hours after transfer, act on the CNS
milieu by secreting proinflammatory cytokines. Such acti-
vation would enable glial cells to process and present pro-
tein antigen, and render BBB endothelium permissive for
invasion by migratory autoimmune T cells. Unexpectedly,
our results suggest that, irrespective of their pathogenic po-
tential, all CNS autoimmune T cells affect the BBB in a
similar fashion.
However, the response patterns of highly and weakly en-
cephalitogenic T cells within the CNS tissues were pro-
foundly full of discrepancy. TMBP-GFP and TDA-MOG-GFP cells,
which transfer severe clinical EAE to syngeneic hosts, up-
regulated two classical activation markers, OX-40 antigen
and IL-2R (Fig. 3), and they turned on production of cyto-
kines (Fig. 4, IFN , IL-10, and IL-2). These functional
changes closely resemble antigen-dependent T cell activa-
tion in vitro. This and the finding that CNS-infiltrating
activated effector T cells show partly down-modulated
TCR–CD3 complexes (12) are compatible with antigen-
dependent activation (27). In striking contrast, weakly en-
cephalitogenic effector T cells (TLE-MOG-GFP or TS100 -GFP
cells) isolated from inflammatory infiltrates in the Lewis rat
were neither demonstrably reactivated (the only notable
change was some increased production of IL-2) (Fig. 4), nor
did they show signs of TCR modulation (not depicted).
Antigen presentation by CNS cells could have led to dis-
parate effects, activation in the case of highly encephalito-
genic T cells, and anergy in the case of the weakly enceph-
alitogenic T cells. Antigen-dependent T cell activation is
critically determined by the circumstances of antigen pre-
sentation within the immune synapse (28). Availability and
affinity of peptide/MHC surface to TCR, the presence of
accessory molecules, and the local cytokine milieu all influ-
ence the level of T cell activation, and, thus, determine the
Figure 7. Quantitative chemo-
kine mRNA expression in the
CNS. The relative amount of
mRNA transcripts for (A) MCP-1
and (B) MIP-1  was analyzed
from spinal cord tissue of MBP-
EAE (MBP), S100 -EAE (S100),
and control animals (control) by
dot blot hybridization at days 2
and 4 after transfer. Note the
massive up-regulation of MCP-1
and MIP-1  mRNA in the CNS
of TMBP cell–treated, but not in
the TS100  cell–treated, animals.
Amplification of  -tubulin and
analysis on ethidium bromide–
stained agarose gels demonstrated
intact RNA in all samples (not
depicted). The data were con-
firmed in a second set of inde-
pendently prepared samples.Reactivation of Autoreactive T Cells in the Target Organ 194
character of the subsequent immune response. Depending
on the relative strength of the signal, the responding T cell
unfolds its repertoire of gene expression in a graded fash-
ion, ranging from complete activation with proliferation
and secretion of a full mediator spectrum to the other ex-
treme, a state of anergy (29).
These general principles govern immune reactions
within and outside of the CNS, but note that immune re-
activity in the CNS adheres to additional rules. The resting
CNS tissues constitute a milieu hostile to immune re-
sponses. Production of MHC determinants, costimulatory
factors, cell adhesion molecules, proinflammatory media-
tors, and other structures required for productive immune
responses are normally suppressed in the healthy CNS (30).
Neurons play a pivotal role in this down-regulation (31).
However, suppression of immune genes can be overcome,
either by application of overwhelming proinflammatory
stimuli or by compromised neuronal function (30).
Thus, within the CNS, several diverse factors may mod-
ulate antigen presentation. One of these relates to the acti-
vation of locally available APCs. For example, astrocytes
are inducible to express MHC class II determinants, but
they do not normally produce costimulatory molecules in
levels required for full T cell activation. Presentation of au-
toantigen by partly activated astrocytes may suppress T cell
activation (32), induce anergy (33), or may divert T cells to
the Th2 activation pathway (34). Indeed, studies involving
transgenic mice carrying brain-reactive T cells reported on
tolerance induction of the transgenic T cell population
within the CNS (35). However, in our model, there was
no evidence of anergy induction or immune deviation.
When isolated from CNS infiltrates, the weakly pathogenic
T cells responded with cytokine production (Fig. 5) and
full proliferation (not depicted) upon exposure with spe-
cific antigen.
Because availability of autoantigen for antigen presenta-
tion within the target organ may influence the intensity of
T cell responses in the CNS, we locally supplied soluble
S100  or MOG protein to spinal cords infiltrated by
TS100 -GFP or TLE-MOG-GFP cells, respectively. Within hours,
the resting infiltrate T cells became activated, followed by
up-regulation of proinflammatory cytokines (Fig. 6 and Fig.
S2 A) and monocyte chemoattractants (Fig. S2 A). At
present, it is not clear why intrathecal antigen injection ag-
gravated clinical disease in LE-MOG-EAE, but much less in
S100 -EAE. It remains to be shown whether activation-
induced cell death (AICD) of T cells (36, 37) is involved af-
ter activation through soluble antigen. This mechanism is
known to accelerate naturally occurring cell death of effec-
tor T cells within the CNS (38–40). Higher susceptibility of
TS100 -GFP cells toward AICD might explain the transient
nature of the clinical effects after S100  injection (Fig. 6 A).
A less plausible explanation would involve different types of
antigen-presenting cells in S100 - versus MOG-EAE.
Peripheral antigen expression might modulate the reacti-
vation capacity of encephalitogenic T cells when they enter
the CNS. It should be noted that S100  differs significantly
from MBP in terms of tissue distribution and physiochemi-
cal properties. MBP and S100  are both major compo-
nents of the CNS, where they are produced by oligoden-
drocytes and astrocytes, respectively. Additionally, both
proteins can be detected in immune organs where they
may modulate the composition and functional activity of
their respective T cell repertoires. In this respect, S100  is
ubiquitously expressed throughout the body and can be de-
tected in many different tissues and cell types (41–48), sug-
gesting that the S100  repertoire may be exposed to a
higher level of tolerogenic signaling. Therefore, the inabil-
ity of active immunization or the adoptive transfer of TS100 
cells to initiate classical EAE could be mediated by tolero-
genic signals in the periphery. However, the only available
evidence for stimulation of S100  cells in the periphery are
slight increases in the expression of IL-2 and IFN  mRNA
transcripts within the spleen (Fig. 4). This does not result in
classical anergy because TS100 -GFP cells recovered from the
spleen still produce IFN  (Fig. 5) and proliferate in re-
sponse to S100  in vitro (Table III).
Unequal availability or distribution of autoantigen does
not explain why MOG-specific T cells are highly encepha-
litogenic in DA rats, but only weakly so in the Lewis strain.
There is evidence that genetic factors codetermine the re-
sult of antigen-dependent T cell activation in the CNS. In-
deed, studies of MOG-specific T cells from Lewis rats con-
genic for diverse MHC haplotypes indicate that genes
located within the MHC determine the level of pathoge-
nicity of these myelin autoimmune T cells (reference 49
and unpublished data). Highly pathogenic MOG-specific T
cell responses were obtained in LEW.1A rats that express
the same class II (RT1.B/Da) MHC haplotype as DA rats.
In contrast, MOG-specific TCLs derived from LEW.1N
(RT1.B/Dn) and LEW.1W (RT1.B/Du) were only weakly
pathogenic, reproducing the results obtained using Lewis
MOG-specific TCLs. We are currently investigating the
role of the MHC–peptide–TCR complex interactions in
controlling the level of T cell activation in the CNS in
more detail in these models.
The intensity of early T cell activation within the CNS
milieu profoundly affects the cellular composition of the
inflammatory infiltrate. As described previously, EAE mod-
els with severe and mild clinical disease strikingly differ by
the frequency of activated macrophages within the CNS
infiltrates (50). Activated macrophages are the crucial effec-
tor cell population in EAE; selective depletion and inacti-
vation of macrophages profoundly suppresses clinical dis-
ease, but leaves the T cell component of the inflammatory
infiltrate relatively intact (51, 52). Several observations sug-
gest that the CC chemokines MCP-1 and MIP-1  play a
crucial role in mediating macrophage recruitment into the
CNS in EAE (53). There is a positive correlation between
the temporal expression of MCP-1 and MIP-1  in the
CNS and the inflammatory response in animals with EAE
(21). Moreover, antibodies directed against these chemo-
kines suppress disease in adoptive transfer and active EAE
(54, 55). MCP-1 and MIP-1  are both expressed in similarKawakami et al. 195
levels by our TGFP cell lines (Table I). Experiments using
transgenic mice deficient for MCP-1 revealed that, whereas
mutant MCP-1 / –derived T cells induced disease in
wild-type recipients, the converse was not true, indicating
that the MCP-1 necessary for disease induction is not pro-
duced by the effector T cells, but rather by other cells
within the CNS parenchyma (56). Other works support
this view (16, 57).
Our finding that weakly pathogenic TLE-MOG-GFP and
TS100 -GFP cells fail to induce strong MCP-1 and MIP-1  re-
sponses in the CNS correlates well with the low numbers of
activated macrophages recruited into the CNS and may be
due to the failure of the T cells to express IFN  and TNF 
in the CNS. These proinflammatory cytokines exert pleio-
tropic effects in EAE and can act on endothelial cells, micro-
glial cells, and astrocytes. Critically important, they are both
strong inducers of MCP-1 and MIP-1  and induce chemo-
kine expression in a wide variety of cell types (58–59).
Our present work identifies the level of T cell activation
within the CNS as a critical checkpoint that determines
whether or not T cell infiltration initiates macrophage re-
cruitment and subsequently clinical disease in EAE. This
regulatory cascade may be extended to other tissue-specific
autoimmune diseases. Indeed, a similar checkpoint has
been postulated in the NOD mouse diabetes model that
determine progression from the infiltration of the pancreas
by T cells to the actual destruction of the islet cells and on-
set of clinical diabetes (60). Our results imply that the level
of activation reached by an infiltrating effector T cell
within the target organ determines the detrimental charac-
ter of the inflammatory infiltrate. This critical level of acti-
vation can be influenced by the nature of the target autoan-
tigen (e.g., MBP vs. S100  in the Lewis rat) as well as
genetic factors as demonstrated by the differential pathoge-
nicity of the MOG-specific T cell response in Lewis and
DA rats. Understanding these mechanisms may lead to
novel therapeutic strategies that selectively disable the sig-
naling pathways that lead to clinical autoaggression, while
leaving intact a benign T cell infiltrate that may actually
promote regeneration and tissue repair (61).
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